Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics.

  title={Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics.},
  author={P. O'Grady and K. Yee and R. Lins and B. Mangold},
  journal={British journal of clinical pharmacology},
  volume={48 3},
  • P. O'Grady, K. Yee, +1 author B. Mangold
  • Published 1999
  • Medicine
  • British journal of clinical pharmacology
  • AIMS Fosinoprilat, the active product of fosinopril, is eliminated by an hepatic pathway in addition to the renal pathway shared by other angiotensin converting enzyme inhibitors (ACEIs). This study aimed to determine whether impaired renal function affects the pharmacokinetics and pharmacodynamics of a combination of fosinopril and hydrochlorothiazide (HCTZ). METHODS The study had a parallel-group design comparing patients with renal impairment and body-mass-index-matched normal controls… CONTINUE READING
    10 Citations
    Renoprotective effects of thiazides combined with loop diuretics in patients with type 2 diabetic kidney disease
    • 11
    Angiotensin-converting enzyme inhibition but not angiotensin II receptor blockade regulates matrix metalloproteinase activity in patients with glomerulonephritis.
    • 44
    • PDF
    Degradation of hydrochlorothiazide in water
    • 35


    Pharmacokinetics of fosinopril in patients with various degrees of renal function
    • 84
    Disposition of fosinopril sodium in healthy subjects.
    • 85
    Pharmacokinetics of hydrochlorothiazide in patients with congestive heart failure.
    • 37